HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Breaching the blood–brain barrier: Researchers intensify quest for ‘holy grail of neuro-oncology’
-
- ASCO makes headway to advance national cancer moonshot initiative
- ASTRO members receive fellows designation
- Nationwide Children’s Hospital names director of cellular therapy, cancer immunotherapy
- Physician–author passionate about listening to patients’ stories, telling his own
- Research collaboration designed to better define real-world effectiveness of immunotherapies
- Society of Surgical Oncology releases ‘Choosing Wisely’ recommendations
- NIH awards $55 million to support Precision Medicine Initiative Cohort Program
- Balancing hope and realism: It may be time to adjust the sails John Sweetenham, MD, FRCP, FACP
-
- FDA approves Syndros for cancer, AIDS indications
- FDA grants fast track status to MM-121 for NSCLC
- FDA grants Jakafi breakthrough designation to treat acute GVHD
- FDA grants Opdivo breakthrough therapy designation for advanced bladder cancer
- Allogeneic HSCT appears safe, effective for older patients with AML
- Biomarker expression may predict metastasis in uveal melanoma
- Cancer center advertising expenditures more than triple since 2005
- Higher costs not associated with improved OS in myelodysplastic syndrome
-
- Outcomes, treatment strategies vary among patients with upper extremity venous thrombosis
- Racial differences in breast density may affect cancer risk assessment, screening
- Refined dosing strategies may improve perioperative treatment of patients with hemophilia A
- Surgery improves outcomes in advanced NSCLC, yet remains underutilized
- ARQ 087 appears safe for treatment of intrahepatic cholangiocarcinoma
- Binimetinib improves PFS, ORR in NRAS–mutant melanoma
- Black women with breast cancer less likely to undergo BRCA testing, risk-reducing surgery
- Cabozantinib improves outcomes in patients with advanced renal cell carcinoma
-
- DFS can serve as surrogate for OS in localized prostate cancer
- Pembrolizumab demonstrates significant clinical activity in heavily pretreated HNSCC
- Risk-reducing procedures decrease libido, increase anxiety in BRCA–positive women
- Rovalpituzumab tesirine demonstrates activity in recurrent, refractory small cell lung cancer
- Sacituzumab govitecan shows promise for metastatic NSCLC
- Sentinel node biopsy noninferior to axillary lymph node dissection for node-positive breast cancer
- Stivarga improves OS for unresectable HCC
- Tumor-infiltrating lymphocytes may predict response after HER-2 blockade therapy
-
- Xilonix improves outcomes in advanced colorectal cancer
- Monoclonal antibodies provide ‘huge step forward’ in treating multiple myeloma